AstraZeneca: COVID-19 vaccine 'highly effective' prevention
AstraZeneca said on Monday its vaccine for the novel coronavirus, developed along with the University of Oxford, could be around 90% effective under one dosing regimen.
- World
- Reuters
- Published Date: 10:55 | 23 November 2020
- Modified Date: 10:58 | 23 November 2020
AstraZeneca says late-stage trials of its COVID-19 vaccine were "highly effective'' in preventing disease.
A vaccine developed by AstraZeneca and the University of Oxford prevented 70% of people from developing the coronavirus in late-stage trials, the team reported Monday.
Key researcher Dr. Andrew Pollard said scientists were pleased with the results. He said researchers found that if people were given a half dose followed by a full dose, rather than two full doses, protection rose to about 90%.
"These findings show that we have an effective vaccine that will save many lives," he said.
Two other drugmakers, Pfizer and Moderna, last week reported preliminary results from late-stage trials showing that their COVID-19 vaccines were almost 95% effective.
- China launches Moon probe to bring back lunar rocks
- Brazil reports 302 COVID-19 deaths, toll at 169,485 - health ministry
- Biden's pick for U.N. envoy will find waning American influence
- Trump campaign to ask appeals court to halt Biden win in Pennsylvania
- Biden to choose ex-Fed chair Yellen as first woman Treasury secretary, allies say